Molecular Partners AG
Index- P/E- EPS (ttm)-2.06 Insider Own- Shs Outstand32.32M Perf Week0.82%
Market Cap197.20M Forward P/E12.61 EPS next Y0.55 Insider Trans- Shs Float26.77M Perf Month-64.51%
Income-63.60M PEG- EPS next Q-1.04 Inst Own4.10% Short Float0.07% Perf Quarter-73.65%
Sales9.70M P/S20.33 EPS this Y18.10% Inst Trans0.09% Short Ratio1.08 Perf Half Y-53.97%
Book/sh8.16 P/B0.85 EPS next Y-85.37% ROA51.00% Target Price34.13 Perf Year-
Cash/sh10.34 P/C0.67 EPS next 5Y- ROE70.10% 52W Range5.92 - 32.04 Perf YTD-64.03%
Dividend- P/FCF1.89 EPS past 5Y- ROI-56.00% 52W High-79.90% Beta-
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low8.78% ATR0.82
Employees163 Current Ratio10.00 Sales Q/Q1148.40% Oper. Margin- RSI (14)17.39 Volatility6.74% 5.54%
OptionableNo Debt/Eq0.02 EPS Q/Q443.90% Profit Margin- Rel Volume2.59 Prev Close6.90
ShortableYes LT Debt/Eq0.02 Earnings- Payout0.00% Avg Volume16.16K Price6.44
Recom2.00 SMA20-40.13% SMA50-62.74% SMA200-66.69% Volume30,286 Change-6.67%
Apr-27-22Downgrade Credit Suisse Neutral → Underperform
Jul-13-21Initiated Cowen Outperform $50
Jul-12-21Resumed SVB Leerink Outperform $36
May-12-22 04:05PM  
May-11-22 01:00AM  
May-03-22 12:00PM  
Apr-27-22 08:02AM  
Apr-26-22 04:05PM  
Apr-23-22 01:00AM  
Apr-13-22 12:00PM  
Mar-24-22 02:00AM  
Mar-17-22 01:00AM  
Mar-15-22 04:30PM  
Feb-25-22 04:30PM  
Feb-11-22 04:10PM  
Feb-10-22 07:13AM  
Jan-28-22 05:57AM  
Jan-23-22 02:28AM  
Jan-18-22 01:00AM  
Jan-13-22 05:00PM  
Jan-12-22 10:13AM  
Jan-11-22 11:37AM  
Jan-10-22 06:51PM  
Jan-06-22 10:00AM  
Jan-05-22 04:05PM  
Dec-15-21 01:00AM  
Dec-14-21 12:16PM  
Dec-12-21 04:00PM  
Dec-09-21 01:00AM  
Dec-06-21 01:00AM  
Dec-03-21 01:00AM  
Nov-30-21 12:48PM  
Nov-24-21 01:00AM  
Nov-16-21 06:49AM  
Nov-04-21 02:00AM  
Oct-28-21 01:00AM  
Oct-20-21 01:00AM  
Sep-03-21 04:05PM  
Aug-26-21 01:00AM  
Aug-09-21 01:00AM  
Jul-13-21 06:55AM  
Jul-08-21 09:04AM  
Jun-15-21 10:00PM  
Jun-13-21 04:00PM  
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a COVID-19 antiviral therapeutic candidate to inactivate SARS-CoV-2 that is in Phase II clinical trials. The company also develops MP0310, which is in Phase I clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive solid tumors. In addition, it is developing MP0423, a candidate for treating COVID-19 through a single molecule; MP0533, an immune activator for multi-specific treatment of acute myeloid leukemia; and MP0250, a multi-specific DARPin molecule that targets vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Further, the company develops CD3 T-Cell targeting and peptide MHC therapeutic platforms. Molecular Partners AG has strategic partnerships with Allergan, Inc. and Amgen SA for ophthalmology; collaboration with Novartis AG to develop, manufacture, and commercialize DARPin program; and collaboration with AGC Biologics and Baccinex to support development of anti-COVID-19 program. The company was founded in 2004 and is headquartered in Schlieren, Switzerland.